CPPOpt Guided Therapy; Assessment of Target Effectiveness and Safety

  • Research type

    Research Study

  • Full title

    A randomized clinical trial assessing the effect of “optimal” cerebral perfusion pressure monitoring in the management of severe traumatic brain injury

  • IRAS ID

    219952

  • Contact name

    Ari Ercole

  • Contact email

    ae105@cam.ac.uk

  • Sponsor organisation

    Clinical Trial Center Maastricht (CTCM)

  • Clinicaltrials.gov Identifier

    NCT02982122

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    In the hours and days following a severe traumatic brain injury, the patient is vulnerable to further brain damage caused by abnormalities in brain blood flow causing alterations in the delivery of oxygen and nutrients. Therefore, a focus of patient management on the neurocritical care unit, is to monitor and prevent abnormalities in the brain blood flow.
    One of the primary techniques employed in the management of these patient’s brain blood flow is monitoring and manipulating the pressure that drives brain blood flow – the cerebral perfusion pressure (CPP). This is calculated simply as the arterial blood pressure minus the pressure within the skull and is a standard approach in critical care units.
    However, which level of CPP is best for each particular patient is currently unknown. In fact, current guidelines indicate the same level of CPP for every patient. This research aims to provide the treating medical team with guidance as to what CPP should be aimed for in a brain trauma patient throughout their time on the critical care unit. The technique uses a computerized analysis of the patients’ brain vessel function and CPP to suggest the ‘optimal’ CPP (CPPopt).
    The purpose of this study are to assess the feasibility and safety of targeting CPPopt compared to standard CPP management.

  • REC name

    London - Camberwell St Giles Research Ethics Committee

  • REC reference

    17/LO/1119

  • Date of REC Opinion

    30 Oct 2017

  • REC opinion

    Further Information Favourable Opinion